Based in Seattle, Washington, Omeros Corporation is a leading biopharmaceutical company committed to discovering, developing, and commercializing innovative small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, complement-mediated diseases, and various disorders. The company is publicly traded on the NASDAQ under the ticker symbol "OMER."
Established in 1994 by Dr. Gregory A. Demopulos, Omeros has been at the forefront of the biotech industry for over two decades. The firm's groundbreaking research involves harnessing the power of the immune system and the biological pathways critical to its functioning. Central to this effort is Omeros' focus on the complement system, which is an essential component of the immune system that plays a pivotal role in inflammation and is implicated in a wide variety of autoimmune and inflammatory diseases.
The company's most successful drug on the market to date is Omidria, a solution used during cataract surgery or intraocular lens replacement to prevent pupil constriction and to reduce postoperative eye pain. Beyond Omidria, Omeros is bringing a broad pipeline of novel therapeutics to the fore. These developments are drawn from the company's proprietary PharmacoSurgery® platform, which is based on the concept of using currently marketed drugs in new ways during surgery to improve clinical outcomes.
Investors' interest in Omeros spiked after the company received breakthrough therapy designation from the U.S. Food and Drug Administration (FDA) for its complement inhibitor, narsoplimab, for patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA). Meanwhile, the European Medicines Agency (EMA) has granted orphan drug designation and positive opinion on eligibility to apply for PRIME designation for narsoplimab, suggesting strong regulatory support.
Further, the company is also advancing its pipeline in other therapeutic areas, including addiction disorders, hematologic disorders, and multiple types of cancers.
As a pioneer in the biotech sector, Omeros Corp prioritizes transparency, ethics, and social responsibility. Its values of integrity, mutual respect, and teamwork are key drivers of its scientific innovation and success. Looking to the future, Omeros Corporation continues its path of discovery and innovation, aiming to provide better outcomes for patients and create value for its shareholders.